Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 20 2024
0mins
Source: PRnewswire
Special Meeting Adjournment: Kintara Therapeutics has adjourned its Special Meeting of Stockholders originally scheduled for September 20, 2024, due to insufficient votes on key proposals related to increasing authorized shares and reincorporation from Nevada to Delaware. The meeting will reconvene on October 4, 2024.
Merger with TuHURA Biosciences: The adjournment is linked to Kintara's proposed merger with TuHURA Biosciences, which is developing immuno-oncology therapies. Both companies are preparing for a Phase 3 trial of TuHURA's lead product candidate, IFx-2.0, aimed at enhancing cancer treatment efficacy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
